Tirzepatide, initially developed to combat type 2 diabetes, has demonstrated additional benefits in safeguarding the cardiovascular system and acting as a powerful weight loss adjunct. It is a synthetic analog of gastric inhibitory polypeptide (GIP) with concurrent glucagon-like peptide-1 (GLP-1) functionality. This dual action enables Tirzepatide to reduce blood glucose levels, enhance insulin sensitivity, promote satiety, and expedite weight reduction.
Promising Clinical Advances
Our clinical trials with Cellgenic Lyophilized Exosomes have shown promising results in orthopedic regenerative therapies.